GILD241220C99000
- 0.11
- 0.000.00%
Gilead Sciences Newsroom
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
The former global development head of Sanofi (SNY.US) has joined Gilead (GILD.US).
Before joining Gilead (GILD.US), Dr. Dietmar Berger served as CMO and Global Development Head at Sanofi (SNY.US).
Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Truist Financial Maintains Gilead Sciences(GILD.US) With Hold Rating
Gilead Sciences (GILD) Gets a Hold From Truist Financial
Gilead Gets Key European Backing for Liver-Disease Treatment
Gilead Sciences Says Committee For Medicinal Products For Human Use Of European Medicines Agency Recommends Seladelpar For Treatment Of Primary Biliary Cholangitis In Combination With Ursodeoxycholic Acid (UDCA) In Adults With Inadequate Response To...
Express News | Gilead: Final European Commission Decision Is Anticipated in Q1 of 2025
Express News | Gilead’s Seladelpar Receives Positive Chmp Opinion for Primary Biliary Cholangitis
Gilead Sciences appoints a former Sanofi executive as Chief Medical Officer.
Globe News on December 13 | Gilead Sciences announced on Thursday the appointment of former Sanofi executive Dietmar Berger as Chief Medical Officer, succeeding Merdad Parsey, who is set to depart early next year. Berger will join on January 2, having previously served as Chief Medical Officer and Global Development Head at French pharmaceutical giant Sanofi, where he led the development science, Global Strategy, and Operation in key therapeutic areas of the company. As Berger joins Gilead, the pharmaceutical company is intensifying its focus on cancer treatments and therapies for inflammatory diseases. The company stated that Berger will be responsible for overseeing the medical strategy.
Gilead Sciences: Berger to Succeed Merdad Parsey on Jan. 2
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
Express News | Gilead Sciences Appoints Dietmar Berger, Md, Phd, as Chief Medical Officer
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
Is Gilead Sciences (GILD) Stock Undervalued Right Now?
Piper Sandler Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $99 to $115